Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Paroxysmal Hypothermia in Two Patients with Multiple Sclerosis.
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis.
MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients.
Scrub typhus with longitudinally extensive transverse myelitis.
Very early MS -- insights from MRI.
Using a highly abbreviated California Verbal Learning Test-II to detect verbal memory deficits.
The translational biology of remyelination: Past, present, and future.
Pain Research Forum: application of scientific social media frameworks in neuroscience.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
Prevalence of stress urinary incontinence in women with multiple sclerosis.
The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
The use of aminopyridines in neurological disorders.
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
The role of tumour necrosis factor α in the pathogenesis of multiple sclerosis, and pentoxifylline as a possible pharmacotherapeutic intervention.
Laquinimod CHMP/EMA opinion
Diagnostic Ability of a Linear Discriminant Function for Spectral-Domain Optical Coherence Tomography in Patients with Multiple Sclerosis.
A touch of MS: Therapeutic mislabeling.
The next generation of exoskeletons: lighter, cheaper devices are in the works.
Endocannabinoids and neurodegenerative diseases.
Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.

Pages